---
title: "600252.SH (600252.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600252.SH/news.md"
symbol: "600252.SH"
name: "600252.SH"
parent: "https://longbridge.com/en/quote/600252.SH.md"
datetime: "2026-03-07T06:20:15.494Z"
locales:
  - [en](https://longbridge.com/en/quote/600252.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600252.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600252.SH/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/600252.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/600252.SH/news.md)


# 600252.SH (600252.SH) — Related News

### [Zhongheng Group's subsidiary Lummy has two products selected for the 2025 Beijing drug centralized procurement](https://longbridge.com/en/news/277769699.md)
*2026-03-04T11:26:00.000Z*
> According to Zhongheng Group, the Beijing Medical Security Bureau recently officially announced the selection results of

### [Zhongheng Group: Some products of its holding subsidiaries and grand-subsidiaries are expected to be selected for the national centralized procurement of pharmaceuticals for follow-up purchases](https://longbridge.com/en/news/275882585.md)
*2026-02-13T10:07:17.000Z*
> Zhongheng Group announced that its holding subsidiary Chongqing Lummy Pharmaceutical and its wholly-owned subsidiary Hun

### [Zhitong A-share lock-up release overview | February 11](https://longbridge.com/en/news/275531609.md)
*2026-02-11T01:01:04.000Z*
> On February 11th, a total of 1 listed company had its restricted shares unlocked, with a total market value of approxima

### [Zhongheng Group: The holding subsidiary Hunan Kangyuan has received the approval notice for the drug supplement application](https://longbridge.com/en/news/275108891.md)
*2026-02-06T10:14:09.000Z*
> Zhongheng Group's subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd. has received the notification of approval for the s

### [Zhongheng Group: The holding subsidiary's nano carbon iron suspension injection combined radiotherapy Phase II clinical trial has obtained ethical approval](https://longbridge.com/en/news/274295044.md)
*2026-01-30T10:58:27.000Z*
> Zhongheng Group announced that its holding subsidiary, Chongqing Lummy Pharmaceutical Co., Ltd.'s subsidiary, Sichuan Yi

### [Zhongheng Group: It is expected that the annual net profit for 2025 will be a loss of 250 million to a loss of 450 million](https://longbridge.com/en/news/274137457.md)
*2026-01-29T11:03:33.000Z*
> Zhongheng Group announced that it expects to achieve a net loss attributable to the owners of the parent company of betw

### [Zhongheng Group: It is expected that the annual net profit attributable to shareholders of the listed company will be negative in 2025](https://longbridge.com/en/news/272173334.md)
*2026-01-11T09:11:03.000Z*
> Zhongheng Group announced that it expects the annual net profit attributable to shareholders of the listed company for 2

### [Zhongheng Group: Provides nearly 10 million yuan in guarantees for its holding subsidiary](https://longbridge.com/en/news/271205779.md)
*2025-12-31T10:59:43.000Z*
> Zhongheng Group announced that in order to meet the operational needs of its holding subsidiary Zhongheng Traditional Ch